

Product Data Sheet

Animal-Free IL-36 alpha/IL-1F6 Protein, Human (His)

| Cat. No.: | HY-P700126AF |
|-------------------|---|
| Synonyms: | IL-36 alpha; IL-36α; Interleukin-36 Alpha; FIL1 Epsilon; Interleukin-1 Epsilon; IL-1 Epsilon; Interleukin-1 Family Member 6; IL-1F6; IL36A; FIL1E; IL1E; IL1F6 |
| Species: | Human |
| Source: | E. coli |
| Accession: | Q9UHA7 (K6-F158) |
| Gene ID: | 14440 |
| Molecular Weight: | Approximately 18.05 kDa |

| PROPERTIES | | | | | |
|----------------------|--|--------------------------------|----------------------|------------|--|
| TROPERTIES | | | | | |
| AA Sequence | | | | | |
| | MKIDTPQQGS | IQDINHRVWV | LQDQTLIAVP | RKDRMSPVTI | |
| | ALISCRHVET | LEKDRGNPIY | LGLNGLNLCL | МСАКVGDQРТ | |
| | LQLKEKDIMD | LYNQPEPVKS | F L F Y H S Q S G R | NSTFESVAFP | |
| | GWFIAVSSEG | GCPLILTQEL | GKANTTDFGL | TMLF | |
| | | | | | |
| Diele sieel Astivity | Manager last the ability to the | | PDMCs The ED forthis | | |
| Biological Activity | Measure by its ability to induce IL-8 secretion in human PBMCs. The ED ₅₀ for this effect is <0.7 ng/mL. | | | | |
| Appearance | Lyophilized powder. | | | | |
| Appearance | Lyophilized powder. | | | | |
| Formulation | Lyophilized from a solution containing 1X PBS, pH 7.4. | | | | |
| ronnaation | Lyophilized nonra solutio | in containing 1X r b3, pri 7.4 | | | |
| Endotoxin Level | <0.1 EU per 1 µg of the protein by the LAL method. | | | | |
| Endotoxin Ecret | | the Ene method. | | | |
| Reconsititution | It is not recommended to reconstitute to a concentration less than 100 μ g/mL in ddH ₂ O. | | | | |
| | | | | | |
| Storage & Stability | Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier pr | | | | |
| | recommended to freeze aliguots at -20°C or -80°C for extended storage. | | | | |
| | | | | | |
| Shipping | Room temperature in continental US; may vary elsewhere. | | | | |
| | | | | | |

DESCRIPTION

Background

IL-36 alpha/IL-1F6 protein, a cytokine, binds to and signals through the IL1RL2/IL-36R receptor, activating the NF-kappa-B and MAPK signaling pathways in target cells, thereby contributing to a pro-inflammatory response. As part of the IL-36 signaling system, it is believed to be present in epithelial barriers and involved in local inflammatory responses, sharing similarities with the IL-1 system through the coreceptor IL1RAP. IL-36 alpha/IL-1F6 appears to play a crucial role in skin inflammatory responses by influencing keratinocytes, dendritic cells, and indirectly impacting T-cells, promoting tissue infiltration, cell maturation, and cell proliferation. In cultured keratinocytes, it induces the expression of various chemokines and pro-inflammatory cytokines, such as CCL3, CCL4, CCL5, CCL2, CCL17, CCL22, CL20, CCL5, CCL2, CCL17,

CCL22, CXCL8, CCL20, CXCL1, TNF-alpha, IL-8, and IL-6. Additionally, IL-36 alpha/IL-1F6 up-regulates the expression of IL-1A, IL-1B, and IL-6 in cultured monocytes, promotes cell maturation in myeloid dendritic cells, and facilitates dendritic cell maturation while driving T-cell proliferation in monocyte-derived dendritic cells. Its interaction with TMED10 mediates translocation from the cytoplasm into the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) and subsequent secretion. Furthermore, IL-36 alpha/IL-1F6 may contribute to pro-inflammatory effects in the lung.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA